SCHEMBL20135357

SCHEMBL20135357

CC1(c2ccc(C(=O)O)cn2)CC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.44
RARB P10826 1/20 0.44
RARG P13631 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
PPARG P37231 1/20 0.44
RXRG P48443 1/20 0.44
HCAR3 P49019 9/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42
GABRE P78334 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134888 0.82 HCAR3 (0.43) RARARARBRARGRXRARXRB
SCHEMBL20135041 0.80 CYP19A1 (0.45) RARARARBRARGRXRARXRB
SCHEMBL20135070 0.77 CYP19A1 (0.63) RARBRARGRXRARXRBRXRG
SCHEMBL20134966 0.77 HCAR3 (0.42) RARARARBRARGRXRARXRB
SCHEMBL28384854 0.75 RXRA (0.56) RARARARBRARGRXRARXRB
SCHEMBL21063395 0.68 P4HA1 (0.47) RARARARBRARGRXRARXRB
SCHEMBL13804209 0.67 GABRP (0.52) RARARARBRARGRXRARXRB
SCHEMBL12310282 0.67 HCAR3 (0.56) RARARARBRARGRXRARXRB
SCHEMBL21063384 0.67 HCAR3 (0.47) RARARARBRARGRXRARXRB
SCHEMBL20135182 0.67 HCAR3 (0.41) RARARARBRARGRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 RARA 2003/4885RARB 1594/4885RARG 2147/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 RARA 1526/4885RARB 1308/4885RARG 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.